Method and pharmaceutical composition for use in the treatment of diabetes

Patent metadata

Field	Value
Publication number	US-10426818-B2
Application number	US-201615560689-A
Country	US
Kind code	B2
Filing date	Mar 23, 2016
Priority date	Mar 24, 2015
Publication date	Oct 1, 2019
Grant date	Oct 1, 2019

Abstract

The present invention relates to an APJ receptor agonist for use in the treatment or the prevention of diabetes.

First claim

The invention claimed is:

1. A method for treating type 2 diabetes comprising
administering to a human subject in need thereof a therapeutically effective amount of (Pyr1)-apelin-13.

2. The method of claim 1 , wherein the therapeutically effective amount ranges from 10 nmol/kg to 200 nmol/kg per day.

3. The method of claim 2 , wherein the therapeutically effective amount ranges from 20 nmol/kg to 40 nmol/kg per day.

4. The method of claim 3 , wherein the therapeutically effective amount is 30 nmol/kg per day.

5. The method of claim 1 , wherein the (Pyr1)apelin-13 is administered to the subject intravenously.

Assignees

• Inserm Insitut National De La Sante Et De La Rech Medicale
• Univ Toulouse 3 Paul Sabatier
• Ct Hospitalier Universitaire Toulouse
• Inst Nat Sante Rech Med
• Univ Paul Sabatier Toulouse

Inventors

• Valet Philippe
• Laurell Isabelle
• Cazals Laurent
• Gourdy Pierre

Classifications

• A61K38/1709 Primary

  from mammals · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title